Rhythm Pharmaceuticals Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 10.7% | 13.3% | 10.8% | 10.1% | 11.5% | 9.1% | 11.2% | 11.4% | 10.7% | 8.4% | 11.9% | 12.5% | 11.0% | |
| 89.3% | 86.7% | 89.2% | 89.9% | 88.5% | 90.9% | 88.8% | 88.6% | 89.3% | 91.6% | 88.1% | 87.5% | 89.0% | |
| 149.2% | 123.3% | 494.8% | 103.2% | 114.1% | 98.4% | 113.1% | 87.2% | 89.7% | 73.4% | 69.4% | 60.9% | 72.2% | |
| 135.4% | 133.6% | 132.4% | 125.2% | 106.4% | 91.2% | 119.5% | 94.7% | 102.2% | 100.4% | 105.8% | 94.7% | 100.4% | |
| 284.6% | 256.9% | 627.9% | 229.1% | 220.5% | 189.6% | 232.6% | 182.0% | 191.9% | 173.8% | 175.2% | 155.6% | 172.6% | |
| -195.3% | -170.3% | -538.7% | -139.2% | -132.0% | -98.6% | -143.7% | -93.4% | -102.6% | -82.2% | -87.1% | -68.1% | -83.6% | |
| 14.0% | 18.8% | 18.3% | 15.8% | 15.8% | 13.0% | 16.5% | 12.0% | 9.2% | 8.1% | 7.6% | 6.4% | 7.7% | |
| -194.6% | -171.0% | -543.3% | -109.3% | -132.3% | -103.7% | -151.1% | -95.4% | -102.9% | -83.0% | -91.7% | -68.6% | -85.1% | |
| 1.6% | 0.8% | 1.2% | 1.6% | -1.0% | -0.2% | 0.2% | 0.7% | 0.2% | -0.1% | 0.9% | 0.6% | 0.4% | |
| -196.2% | -171.8% | -544.4% | -110.9% | -131.2% | -103.5% | -151.4% | -96.1% | -103.1% | -83.0% | -92.6% | -69.2% | -85.6% | |
| -178.7% | -150.5% | -523.4% | -92.1% | -115.4% | -89.8% | -133.4% | -82.7% | -93.1% | -74.5% | -83.6% | -61.8% | -77.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.